[1]Oterdoom L.H., Verweij K.E., Biermann K. Hepatocellular Adenomas and Carcinoma in Asymptomatic. Non-Cirrhotic Type III Glycogen Storage Disease. J Gastrointestin Liver Dis. 2015;24:515-518.
[2]Kishnani P.S., Goldstein J., Austin S.L. Diagnosis and management of glycogen storage diseases type VI and IX: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2019;21:772-789.
[3]Sentner C.P., Hoogeveen I.J., Weinstein D.A. Glycogen storage disease type III : diagnosis, genotype, management, clinical course and outcome. J Inherit Metab Dis. 2016;39:697-704.
[4]Davit-Spraul A., Piraud M., Dobbelaere D. Liver glycogen storage diseases due to phosphorylase system deficiencies : diagnosis thanks to non invasive blood enzymatic and molecular studies. Mol Genet Metab. 2011;104:137-143.
[5]Davit-Spraul A., Costa C., Zater M. Hereditary fructose intolerance: Frequency and spectrum mutations of the aldolase B gene in a large patient's cohort from France--identification of eight new mutations. Mol Genet Metab. 2008;94:443-447.
[6]Bouteldja N., Timson D.J. The biochemical basis of hereditary fructose intolerance. J Inherit Metab Dis. 2010;33:105-112.
[7]Guide de l’alimentation des patients IHF : SFEIM, G2M filière de santé maladies rares 06.2017. Sites : www.sfeim.org et www.filière-g2m.fr.
[8]Aldámiz-Echevarría L, de Las Heras J, Couce ML, et al. Non-alcoholic fatty liver in hereditary fructose intolerance. Clin Nutr 2019 ; pii : S0261-5614(19)30073-1.